Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 18/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636902 | 0.84 | HTT (0.50) | HTTSMN1; SMN2 | |
| SCHEMBL2424622 | 0.83 | HTT (0.49) | HTTSMN1; SMN2 | |
| SCHEMBL13741691 | 0.83 | HTT (0.44) | HRH3HTTSMN1; SMN2 | |
| SCHEMBL3547663 | 0.81 | HTT (0.48) | HRH4HTTSMN1; SMN2 | |
| SCHEMBL14085270 | 0.81 | HTT (0.48) | HRH4HRH3HTTSMN1; SMN2 | |
| SCHEMBL16812295 | 0.81 | APOBEC3A (0.48) | HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL31267936 | 0.80 | HTT (0.47) | HRH4HRH3HTTSMN1; SMN2POLB | |
| SCHEMBL6203854 | 0.79 | POLB (0.53) | HTTSMN1; SMN2POLB | |
| SCHEMBL20952808 | 0.77 | TYRO3 (0.44) | HTTSMN1; SMN2 | |
| SCHEMBL20690381 | 0.77 | GLA (0.53) | HRH4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605752-B1 | Sulfonamides for the treatment of congestive heart failure, their compositions and uses. | CYTOKINETICS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | HRH4 3/4885HRH3 19/4885HTT 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.